Assessment of plasminogen activator inhibitor-1 and von Willebrand factor as a marers of endothelial function in patients with end-stage kidney disease after allotransplantation during a one-year follow-up

To compare circulating pigment epithelium derived factor (PEDF) levels in type 2 diabetes patients (T2D) with and without metabolic syndrome (MetS+/-) to healthy controls and assess PEDF association with plasminogen activator inhibitor-1 (PAI-1) and von Willebrand factor (vWF) as markers of endothelial dysfunction. Fifty T2D individuals and forty healthy controls were included. PEDF, PAI-1, vWF, anthropological parameters, lipids, and markers of insulin resistance were investigated in all subjects. Compared to controls only MetS+ diabetics had higher PEDF levels [14.2 (10.2-16.0) mg/l vs. 11.1 (8.6-14.4) mg/l; p<0.05]. PEDF significantly correlated: positively with body mass index (ρ=0.25), smoking (ρ=0.21), C-reactive protein (ρ=0.22), triglycerides (ρ=0.38), non-HDL-cholesterol (ρ=0.39), apolipoprotein B (ρ=0.38), fasting glucose (ρ=0.22), glycated hemoglobin (ρ=0.24), C-peptide (ρ=0.28), insulin (ρ=0.26); and negatively with HDL-cholesterol (ρ=-0.42) and apolipoprotein A1 (ρ=-0.27). Independent association of PEDF with vWF in T2DMetS- subjects was found. Significantly elevated PEDF in T2DMet+ patients and its association with adverse metabolic profile confirmed PEDF as a marker of insulin resistance. Negative independent association of PEDF with vWF in T2DMetS- patients may reveal its angio-protective role.

Download Full-text

Significant decrease of von Willebrand factor and plasminogen activator inhibitor-1 by providing supplementation with selenium and coenzyme Q10 to an elderly population with a low selenium status

European Journal of Nutrition ◽

10.1007/s00394-020-02193-5 ◽

2020 ◽

Vol 59 (8) ◽

pp. 3581-3590 ◽

Cited By ~ 2

Author(s):

Urban Alehagen ◽

J. Alexander ◽

J. Aaseth ◽

A. Larsson ◽

T. L. Lindahl

Keyword(s):

Coenzyme Q10 ◽

Repeated Measures ◽

Plasminogen Activator Inhibitor ◽

Active Treatment Group ◽

Plasminogen Activator Inhibitor 1 ◽

Low Selenium ◽

Von Willebrand ◽

Willebrand Factor ◽

Activator Inhibitor ◽

Pai 1

Abstract Purpose Endothelial dysfunction and inflammation are conditions which fuel atherosclerosis and ischaemic heart disease. We have previously reported reduced cardiovascular (CV) mortality following supplementation with selenium and coenzyme Q10 to 443 elderly individuals with low selenium status (mean 67 μg/L) for 4 years. Here, we wanted to evaluate a possible association between the supplementation and the plasma concentrations of the von Willebrand factor (vWf), and the plasminogen activator inhibitor-1 (PAI-1), as they, besides other functions, are also strongly associated with endothelial function. Methods In this sub-study, 308 individuals (active substance: 157, placebo: 151) were included. Blood samples were drawn after 6 and 36 months and vWf and PAI-1 were determined in plasma by ELISA. Changes in concentrations of the biomarkers were evaluated by the use of T tests, repeated measures of variance, and ANCOVA analyses. Results The active treatment group presented a lower level of vWf after 36 months compared with the placebo group (1.08 U/mL vs. 5.10 U/mL; p = 0.0007). The results were validated through the repeated measures of variance evaluation. The PAI-1 levels showed an equally significant decrease in the active group (26.2 ng/mL vs. 49.2 ng/mL; p = 0.0002) and were also validated through repeated measures of variance evaluation. Conclusion In this sub-study on elderly receiving selenium and coenzyme Q10, or placebo we found significantly lower levels of vWf and PAI-1 in the active treatment group as compared to the placebo group. We interpret this as a better endothelial function because of the intervention, which accords with a previous finding of reduced CV mortality.

Download Full-text

Aortic endothelial cell von Willebrand factor content, and circulating plasminogen activator inhibitor-1 are increased, but expression of endothelial leukocyte adhesion molecules is unchanged in insulin-dependent diabetic BB rats

Atherosclerosis ◽

10.1016/s0021-9150(99)00344-5 ◽

2000 ◽

Vol 149 (2) ◽

pp. 331-342 ◽

Cited By ~ 2

Author(s):

José C.O Ribau ◽

John A Samis ◽

Yotis A Senis ◽

Donald H Maurice ◽

Alan R Giles ◽

...

Keyword(s):

Endothelial Cell ◽

Leukocyte Adhesion ◽

Plasminogen Activator Inhibitor ◽

Plasminogen Activator Inhibitor 1 ◽

Insulin Dependent ◽

Insulin Dependent Diabetic ◽

Von Willebrand ◽

Willebrand Factor ◽

Activator Inhibitor ◽

Leukocyte Adhesion Molecules

Download Full-text

Continuous Active State of Coagulation System in Patients With Nonthrombotic Inflammatory Bowel Disease

Clinical and Applied Thrombosis/Hemostasis ◽

10.1177/1076029611405034 ◽

2011 ◽

Vol 17 (6) ◽

pp. 600-604 ◽

Cited By ~ 23

Author(s):

Huseyin Alkim ◽

Selime Ayaz ◽

Canan Alkim ◽

Aysel Ulker ◽

Burhan Sahin

Keyword(s):

Plasminogen Activator ◽

Degradation Products ◽

Plasminogen Activator Inhibitor ◽

Protein S ◽

Plasminogen Activator Inhibitor 1 ◽

Inflammatory Bowel ◽

Von Willebrand ◽

Willebrand Factor ◽

Activator Inhibitor ◽

D Dimer

This study was planned for searching possible changes of the total coagulation and fibrinolysis system in inflammatory bowel disease (IBD) in order to obtain some clues for explaining the relation between IBD and hypercoagulability. A total of 24 patients with ulcerative colitis, 12 patients with Crohn disease, and 20 healthy controls were studied. Platelets; prothrombin time (PT); partial thromboplastin time (PTT); fibrinogen; d-dimer; fibrinogen degradation products; protein C; protein S; antithrombin; thrombin time; von Willebrand factor; coagulation factors V, VII, VIII, IX, XI, and XIII; plasminogen; antiplasmin; tissue plasminogen activator; plasminogen activator inhibitor 1; and prothrombin fragments 1 + 2 were studied. Most of the procoagulants (platelets, fibrinogen, von Willebrand factor, coagulation factor IX, and plasminogen activator inhibitor 1) were found increased together with decreases in some anticoagulants (protein S and antithrombin) in IBD. Also the activation markers of coagulation (d-dimer, fibrinogen degradation products, and prothrombin fragments 1 + 2) were all increased. The parameters of the total coagulation–fibrinolysis system were increased in IBD, regardless of the form and the activity of the disease.

Download Full-text

Enhanced thrombin generation, P-von willebrand factor, P-fibrin D-dimer and P-plasminogen activator inhibitor 1: Predictive for venous thrombosis in asparaginase-treated children

Fibrinolysis and Proteolysis ◽

10.1016/0268-9499(94)90248-8 ◽

1994 ◽

Vol 8 ◽

pp. 63-65 ◽

Cited By ~ 19

Author(s):

U. Nowak-Göttl ◽

J.E.A. Wolff ◽

N. Kuhn ◽

J. Boos ◽

B. Kehrel ◽

...

Keyword(s):

Venous Thrombosis ◽

Plasminogen Activator ◽

Von Willebrand Factor ◽

Thrombin Generation ◽

Plasminogen Activator Inhibitor ◽

Plasminogen Activator Inhibitor 1 ◽

Von Willebrand ◽

Willebrand Factor ◽

Activator Inhibitor ◽

D Dimer

Download Full-text

Changes in measures of cognitive function in patients with end-stage kidney disease on dialysis and the effect of dialysis vintage: A longitudinal cohort study

PLoS ONE ◽

10.1371/journal.pone.0252237 ◽

2021 ◽

Vol 16 (5) ◽

pp. e0252237

Author(s):

Karumathil M. Murali ◽

Judy Mullan ◽

Steven Roodenrys ◽

Hicham I. Cheikh Hassan ◽

Maureen Lonergan

Keyword(s):

Cognitive Impairment ◽

Cognitive Function ◽

Kidney Disease ◽

Analysis Of Covariance ◽

End Stage Kidney Disease ◽

Change Scores ◽

Dialysis Vintage ◽

One Year ◽

End Stage

Introduction Prevalence of cognitive impairment increases with worsening severity of chronic kidney disease (CKD) and majority of end-stage kidney disease (ESKD) patients on dialysis have cognitive impairment. Trends of cognitive function (CF) in this population are less well known with published studies reporting conflicting results. Methods We assessed CF in a cohort of non-dialysis CKD and ESKD patients undergoing dialysis using modified mini-mental state examination (3MS), trail-making test (TMT-A & B) scores and Stroop task, and evaluated demographics, comorbidities and depression using Beck depression inventory at baseline. We repeated tests of CF and depression ≥ 1-year after baseline in both groups and compared change scores in CF and depression between ESKD/ CKD sub-groups. Among ESKD patients we compared change scores between patients with dialysis vintage of <1-year and >1-year. Analysis of covariance was used to adjust for the effect of age on these change scores. Results At baseline (N = 211), compared to CKD (N = 108), ESKD (N = 103) patients had significantly worse CF based on 3MS and TMT-A & B scores, and depression scores. On follow-up (N = 160) 3MS scores, especially the memory subscale significantly improved in ESKD, but worsened in CKD, with no significant changes in TMT A /TMT-B, or depression scores after adjusting for age. Among ESKD patients, 3MS, especially memory subscale improved in patients with dialysis vintage <1-year compared to >1-year. The 51 patients who discontinued after baseline assessment had worse baseline CF scores suggesting differential attrition. Conclusion Though baseline cognitive scores were worse in ESKD patients on dialysis, compared to CKD, their 3MS, especially memory subscale improved on follow-up. Among ESKD patients, the improvement was significant only in patients who have been on dialysis for less than one-year which may indicate a beneficial effect of clearance of uraemic toxins. Differential attrition of study subjects may have impacted the observed results.

Download Full-text